Aims PCSK9 inhibitors lower LDL cholesterol and are efficacious at reducing risk of 2 vascular disease, however questions remain about potential adverse effects on 3 cognitive function. We examined the association of LDL cholesterol-lowering genetic 4 variants in PCSK9 with continuous measures of cognitive ability 5
Introduction 1
Therapeutic modification of atherogenic lipoproteins by statins 1 , ezetimibe 2 and 2
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition 3 is an effective 3 strategy to reduce risk of cardiovascular disease (CVD), principally by lowering non-4 HDL-cholesterol 4 . PCSK9 regulates LDL-cholesterol (LDL-C) through hepatic 5 expression of LDL receptors. PCSK9 inhibitors are licensed as LDL-C lowering 6 agents with excellent efficacy and evidence of cardiovascular benefit: the FOURIER 7 trial 3 recently reported that a monoclonal antibody to PCSK9 that lowered LDL-C by 8 59% (~56 mg/dl) led to a 15% reduction in risk of a composite of cardiovascular 9 death, myocardial infarction, stroke, hospitalization for unstable angina or coronary 10 revascularization in patients with established atherosclerotic vascular disease. 11 However, early phase 3 studies showed a potential excess of neurocognitive 12 adverse effects 5 , leading the US FDA to instruct pharmaceutical companies to 13 assess neurocognitive side effects of PCSK9 inhibitors. While, reassuringly, no 14 excess risk was noted in the FOURIER trial 3 or its substudy with detailed cognitive 15 measures 6 , these studies cannot exclude potential adverse effects from longer-term 16 use of PCSK9 inhibitors. An orthogonal approach to obtain reliable information is to 17 exploit genetic variants that mimic pharmacological inhibition of PCSK9. Naturally 18 occurring variation in the gene encoding a drug target can be used to gauge insight 19 on long-term effects of therapeutic modification. So-called drug-target Mendelian 20 randomization 7 exploits the characteristics of genotype for the reliable estimation of 21 both intended and unintended consequences of therapeutic modification of a drug 22 target, as previously demonstrated [8] [9] [10] [11] . 23
24

Methods 25
We used four measures of cognitive ability from UK Biobank (UKB) data: two from 1 baseline (2006) (2007) (2008) (2009) (2010) : fluid reasoning measured in 160,130 individuals (with genetic 2 data, prior to exclusions listed below) and reaction time in 482,187 as they showed 3 good intra-participant longitudinal reliability in n=19,999 participants 12 , and two 4 measured between 2014-15 via the internet: trail making test (TMT) A (processing 5 speed) in 100,587 and B (speed plus executive function) in 100,610, and digit 6 symbol coding (executive function) in 115,933. TMT and reaction time scores were 7 log-transformed due to a positive skew. All measures were standardized to Z-scores. 8
Six independent SNPs (R 2 <0.15) in PCSK9 (referent allele frequencies 9 rs2479394 A = 0.72; rs11206510 C = 0.19; rs2479409 A = 0.65; rs10888897 T = 10 0.39; rs7552841 C = 0.63; rs562556 G = 0.18); orientated so that the effect allele 11 associated with a lower LDL-C were used as genetic variants to proxy therapeutic 12 inhibition of PCSK9. SNPs were selected from the paper by Ference and colleagues 13 in NEJM 13 . In the paper by Ference 13 , seven PCSK9 SNPs were used, however two 14 were found to be moderately correlated (rs2479409 and rs2149041; R 2 =0.37). We 15 therefore removed the SNP with the weaker association with LDL-C (rs2149041) as 16 defined by the P-value 13 , leaving six SNPs (with pair-wise LD R 2 <0.15) described 17 above. The LDL-C association of each of the six PCSK9 SNPs from the Global 18 Lipids Genetics Consortium 14 was used to construct a weighted PCSK9 allele score. 19
Linear regression analyses used the four cognition traits as dependent variables, the 20 weighted PCSK9 score as the independent variable, adjusted for age, sex, GWAS 21 array, and 10 principal components (as provided by UKB). To mimic pharmacological 22 modification of PCSK9, we report results of the PCSK9 allele score scaled to the 23 50mg/dL lower LDL-C achieved in FOURIER. We compared estimates of the PCSK9 24 allele score with cognition traits to those from APOE e4 dosage (excluding rare 25 APOE e2/e4), APOE e4/e4 vs. e3/e3 homozygosity; current vs. never smoking, and 1 5-years of increased cross-sectional age with cognitive traits. As a further positive 2 control, we tested the association of the PCSK9 allele score with risk of CHD in UK 3
Biobank (defined as self-reported physician-diagnosed myocardial infarction and 4 angina). 5
We excluded participants with non-white British ancestry, self-report vs. 6 genetic sex mismatch, putative sex chromosomal aneuploidy, excess heterozygosity, 7
and missingness rate >0.1. We removed one random participant in cases where two 8 individuals were first cousins or closer. Stata v14 and PLINK v1.90 were used for 9
analyses. 10 11
Results
12
The PCSK9 allele score scaled to a 50mg/dL lower LDL-C was associated with lower 13 risk of CHD in UKB (comprising 15,284 cases of myocardial infarction and angina in 14 338,852 individuals; odds ratio: 0.73; 95% CI: 0.60 to 0.90, P = 0.003). The PCSK9 allele score was nominally associated with log reaction time (0.04 SDs 21 higher log reaction time; 95%CI: 0.002, 0.079; P=0.038). For fluid reasoning, the 22 scaled PCSK9 allele score had wide 95% CI (-0.08, 0.07) that included the estimates 23 for the association of 5 years additional age (-0.05 SDs, 95%CI: -0.06, -0.05). Similar 24 patterns were identified for all other cognition traits, meaning that despite the large 25 sample size, the imprecision around the estimates obtained from the PCSK9 allele 1 score meant that we could not exclude a similar magnitude of effect of genetic 2 inhibition of PCSK9 to that seen with the positive controls, including APOEe4 or 3 smoking status for any of the individual cognition traits (Figure) . Notably, point 4 estimates for the association of the PCSK9 allele score and all cognitive ability end-5 points were on the harmful side of unity. 6
In sensitivity analyses, removal of participants that self-reported a 7 neurological condition (~5% of the dataset ref12 ) did not alter the findings, nor did 8 substituting rs2479409 for rs2149041 in the PCSK9 allele score. 9 10 Discussion 11
In this large-scale analysis of individuals from the general population, we used 12 naturally occurring genetic variants in PCSK9 to gauge insight into the effect of 13 lifelong lowering of LDL-C through inhibition of PCSK9 and its association with 14 cognition abilities. Using currently available data in UKB, we were not able to provide 15 definitive evidence on the relationship of PCSK9 genetic variants with cognition 16 traits. While this may have arisen due to lack of power, we note that we were able to 17 show associations of the PCSK9 allele score with risk of prevalent self-reported 18 CHD, and also we note robust associations of conventional risk factors (e.g. age and 19 smoking) and genetic variants (e.g. APOE e4) with the cognitive traits. While the 20 imprecision makes it challenging to draw firm conclusions about an effect (or lack 21 thereof) of life-long LDL-cholesterol lowering by PCSK9 inhibition on cognition, our 22 data highlight the need for additional large-scale genetic analyses. In parallel, 23 continued pharmacovigilance is needed for patients currently treated with PCSK9 24 inhibitors. 25 Standardized beta of cognition trait
